Response to Letter to the Editor: "Risk for Infections During Treatment with Denosumab for Osteoporosis: a Systematic Review and Meta-analysis"

J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa299. doi: 10.1210/clinem/dgaa299.

Authors

Talia Diker-Cohen^{1

2

3}, Dana Rosenberg^{1

3}, Tomer Avni^{1

3}, Daniel Shepshelovich^{1

3}, Gloria Tsvetov^{2

3}, Anat Gafter-Gvili^{1

3}

Affiliations

¹ Medicine A Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
² Institute of Endocrinology, Diabetes and Metabolism, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 32445567
DOI: 10.1210/clinem/dgaa299

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents* / adverse effects
Denosumab / adverse effects
Humans
Osteoporosis* / drug therapy

Substances

Bone Density Conservation Agents
Denosumab